Australia markets closed
  • ALL ORDS

    7,543.60
    +7.50 (+0.10%)
     
  • ASX 200

    7,241.20
    +16.00 (+0.22%)
     
  • AUD/USD

    0.7004
    -0.0090 (-1.27%)
     
  • OIL

    66.22
    -0.28 (-0.42%)
     
  • GOLD

    1,782.10
    +21.40 (+1.22%)
     
  • BTC-AUD

    66,578.66
    -15,366.87 (-18.75%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • AUD/EUR

    0.6187
    -0.0087 (-1.39%)
     
  • AUD/NZD

    1.0371
    -0.0028 (-0.27%)
     
  • NZX 50

    12,676.50
    +6.26 (+0.05%)
     
  • NASDAQ

    15,712.04
    -278.72 (-1.74%)
     
  • FTSE

    7,122.32
    -6.89 (-0.10%)
     
  • Dow Jones

    34,580.08
    -59.71 (-0.17%)
     
  • DAX

    15,169.98
    -93.13 (-0.61%)
     
  • Hang Seng

    23,766.69
    -22.24 (-0.09%)
     
  • NIKKEI 225

    28,029.57
    +276.20 (+1.00%)
     

Eurofins Has Entered a Liquidity Contract With Kepler Cheuvreux

  • Oops!
    Something went wrong.
    Please try again later.
·4-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LUXEMBOURG, October 27, 2021--(BUSINESS WIRE)--Regulatory News:

Eurofins Scientific S.E. ("Eurofins" or the "Company") (Paris:ERF) announces it has signed an agreement with Kepler Cheuvreux to implement a liquidity contract in order to enhance the liquidity of Eurofins’ shares on Euronext Paris (ISIN: FR0014000MR3) (the "Agreement").

The Agreement commences on 1 November 2021, ends on 31 December 2021 and is renewable for one-year periods thereafter. EUR 15 million have been allocated by Eurofins to a liquidity account for the implementation of the Agreement.

This Agreement is in accordance with the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014 on market abuse (MAR); the Commission Delegated Regulation (EU) 2016/908 of 26 February 2016 supplementing Regulation (EU) No. 596/2014 of the European Parliament and of the Council with regulatory technical standards on the criteria, procedure and requirements for the establishment of an admitted market practice and the requirements for maintaining, discontinuing or modifying its conditions of admission; Article 430-15 of Luxembourg law of 10 August 1915, as amended; Applicable regulations of the French Financial Markets Association (AMF), specifically articles 221-3 and 524-4; and AMF decision n° 2021-01 of 22 June 2021, applicable as of 1 July 2021.

This Agreement will be suspended under the conditions referred to in Article 5 of the decision n° AMF 2021-01 of 22 June 2021, or at the request of Eurofins Scientific S.E. for a defined period.

The Agreement may be terminated at any time by Eurofins without notice, or by Kepler Cheuvreux with one month's notice. It will also automatically terminate if Eurofins’ shares are transferred to another stock market.

Notes to Editors:

For more information, please visit www.eurofins.com

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agroscience Contract Research services. Eurofins is also one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, BioPharma Contract Development and Manufacturing, advanced material sciences and in the support of clinical studies. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With 55,000 staff across a decentralised and entrepreneurial network of 900 laboratories in over 50 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 30 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments, travel and events during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005837/en/

Contacts

Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@eurofins.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting